SPOTLIGHT: Lonza buys Genentech plant


Switzerland's Lonza has struck a deal to buy a manufacturing plant in Spain from Genentech for $150 million. Genentech, meanwhile, gained an option to buy a huge new manufacturing plant Lonza is building in Singapore for $290 million plus $70 million in milestones. Lonza expects the FDA to license the new plant in 2010. Lonza gains a short-term pact to produce Avastin in the deal. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.